Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary.
Wedbush reaffirmed their outperform rating on shares of Gossamer Bio (NASDAQ:GOSS – Free Report) in a report released on Wednesday, Benzinga reports. The brokerage currently has a $6.00 price target on the stock. Wedbush also issued estimates for Gossamer Bio’s Q1 2024 earnings at ($0.17) EPS, Q2 2024 earnings at ($0.17) EPS, Q3 2024 earnings […]
Gossamer Bio (NASDAQ:GOSS) PT Lowered to $8.00 themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Wedbush restated their outperform rating on shares of Gossamer Bio (NASDAQ:GOSS – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has a $6.00 price target on the stock. Wedbush also issued estimates for Gossamer Bio’s Q1 2024 earnings at ($0.17) EPS, Q2 2024 earnings at ($0.17) […]
HC Wainwright Reiterates "Buy" Rating for Gossamer Bio (NASDAQ:GOSS) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.